Fundraising Fox
PharmEnable
11 employees on LinkedIn · 13 known investors
Find your way into PharmEnable
Sign up to see every warm intro you have to PharmEnable
- Paths you didn't know you had: your email and LinkedIn already hold routes to the PharmEnable team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
PharmEnable applies AI to small molecule drug discovery, focusing on challenging and data-sparse biological targets that traditional methods struggle to address. The company develops first- and best-in-class therapies and originated as a spin-out from the University of Cambridge.
Founders & leadership
Investors · 13
How we know: Cambridge Angels group's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Martlet Capital's portfolio page · funding news · pharmenabletx.com · Not right? Tell us
How we know: MC Healthcare Ventures's portfolio page · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: funding news · pharmenabletx.com · Not right? Tell us
How we know: funding news · globenewswire.com · Not right? Tell us
Also in the syndicate · 6
Funding
SEC filings, press & company announcements$7.5M disclosed across 1 round · 2023
- $7.5MPre-Series AMay 2023 · 3 sources
MP Healthcare (lead), MP Healthcare Venture Management (MPH) (lead), Arrowfield Capital, Cambridge Enterprise, Heyford Trust, Martlet Capital, o2h Ventures, Parkwalk Advisors, University of Cambridge Enterprise Fund VIII, Wren Capital
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does PharmEnable do?
- PharmEnable applies AI to small molecule drug discovery, focusing on challenging and data-sparse biological targets that traditional methods struggle to address. The company develops first- and best-in-class therapies and originated as a spin-out from the University of Cambridge.
- Who founded PharmEnable?
- PharmEnable was founded by Hannah Sore.
- Who are PharmEnable's investors?
- PharmEnable's investors include Cambridge Angels group, Martlet Capital, MC Healthcare Ventures, Diamond Edge Ventures, O2h Ventures, Parkwalk Advisors, Wren Capital.
- How much funding has PharmEnable raised?
- PharmEnable has disclosed $7.5M raised across 1 round.